Medical/Pharmaceuticals

Immunoforge's 'PF1801' Is Designated as Orphan Drug by FDA

SEOUL, South Korea, Jan. 28, 2021 /PRNewswire/ -- Immunoforge, the company specializing in the development of new drugs for rare musculoskeletal diseases (Representatives: An Seong-Min and Jang Gi-Ho), announced that their new drug candidate PF1801 has been designated as the FDA orphan drug for t...

2021-01-28 22:00 2267

"Right to Work" Is Theme of 16th Global Appeal to End Stigma and Discrimination against Persons Affected by Leprosy to Be Launched with Endorsement of International Trade Union Confederation

TOKYO and BRUSSELS, Jan. 28, 2021 /PRNewswire/ -- The 16th Global Appeal to End Stigma and Discrimination against Persons Affected by Leprosy will be launched in an online ceremony onJanuary 31, 2021, World Leprosy Day. Global Appe...

2021-01-28 22:00 1644

Transnetyx, One Codex Build Strategic Partnership to Provide a Complete Microbiome Analysis Service for Both Mice and Humans

MEMPHIS, Tenn., Jan. 27, 2021 /PRNewswire/ -- Transnetyx, Inc. announced today its collaboration with One Codex on an end-to-end microbiome sequencing and analysis service. This offering will be driven by Transnetyx's wide-reaching global footprint in the model organism community and One Codex's ...

2021-01-28 03:29 1508

Neurophth Therapeutics Further Expands Ocular Gene Therapy Expertise with Appointment of Qiutang Li, Ph.D., as Chief Scientific Officer

WUHAN, China and NEWARK, Del., Jan. 27, 2021 /PRNewswire/ -- Wuhan Neurophth Biotechnology Ltd., a fully-integrated genetic medicines company developing AAV-delivered gene therapies for the treatment of ocular diseases, today announced the appointment of Qiutang Li, Ph.D., as Chief Scientific Off...

2021-01-27 21:00 1826

Singapore-based Osteopore International Collaborates With Maastricht University Medical Centre To Develop Implant Solution That Prevents Leg Amputations

* Osteopore and Maastricht University Medical Centre has developed a first-of-its-kind, bioresorbable bone implant solution that prevents leg amputations in patients with severe lower leg fractures * Osteopore and National Additive Manufacturing Innovation Cluster have formed a partnership to...

2021-01-27 17:57 2140

Medeon Announces Positive Clinical Results for XFLO Minimally Invasive BPH Treatment Device

TAIPEI, Jan. 27, 2021 /PRNewswire/ -- Medeon Biodesign, Inc. (TPEx: 6499), a Taiwan publicly traded medical device company, is pleased to announce positive interim results of the EXPANDER-1 Clinical Study for its flagship product the XFLO™ Expander System, an innovative, minimally invasive Benign...

2021-01-27 17:41 2434

Samsung Biologics, National OncoVenture, and Eutilex Obtain IND Approval from FDA

INCHEON, South Korea, Jan. 26, 2021 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) announced another successful Investigational New Drug (IND) clearance from the FDA for its client to begin clinical trials on a cancer immunotherapy, furthering the company's track record as a premiere CDO serv...

2021-01-27 08:26 6503

Biocytogen Subsidiary Eucure Biopharma Reports First Patient Enrolled in anti-CTLA4 Phase I Trial in China

BOSTON and BEIJING, Jan. 26, 2021 /PRNewswire/ -- Eucure Biopharma, a subsidiary of Biocytogen, announced the first patient enrollment for a Phase I clinical trial inChina to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of its anti-CTLA4 monoclonal antibody (YH001)...

2021-01-26 23:45 1593

Maypharm Announces New Product METOX on Times Square in New York

SEOUL, South Korea and NEW YORK, Jan. 26, 2021 /PRNewswire/ -- Maypharm announces new botulinum toxin, METOX onJanuary 26, 2021. METOX is an effective solution for smoothing any kind of wrinkles from moderate to severe, caused by daily active facial movements.

2021-01-26 17:00 1962

I-Mab and MorphoSys Announce First Patient Dosed in U.S. Phase 1 Study of TJ210/MOR210 in Patients with Advanced Cancer

SHANGHAI, China and PLANEGG/MUNICH, Germany, Jan. 25, 2021 /PRNewswire/ -- I-Mab (Nasdaq: IMAB), and MorphoSys (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) today announced that the first patient has been dosed in a phase 1 dose escalation study to evaluate the safety, tolerabili...

2021-01-26 05:05 3750

BioNTech and Fosun Pharma Receive Authorization for Emergency Use in Hong Kong for COVID-19 Vaccine

MAINZ, Germany and SHANGHAI, China, 25 Jan. 2021 /PRNewswire/ -- BioNTech SE  (Nasdaq: BNTX, "BioNTech" or "the Company") andShanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma" or "Group"; Stock Code: 600196.SH, 02196.HK) today announced that according to the Food and Health Bureau of ...

2021-01-26 01:18 6419

VolitionRx Limited Opens its New Manufacturing Facility in Belgium

AUSTIN, Texas, Jan. 25, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced the opening of "Silver One", its 10,000 square foot dedicated manufacturing facility located on the same science park as its Research and Development laboratory in Isnes,Belgium. Vol...

2021-01-25 21:45 8587

China Biologic Announces Extraordinary General Meeting of Shareholders

BEIJING, Jan. 25, 2021 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced that it has called an extraordinary general meeting of shareholders (the "EGM...

2021-01-25 21:44 9758

DWHP Announces Extension of The Expiration Time of Its Tender Offer

PARK CITY, Utah, Jan. 22, 2021 /PRNewswire/ -- DW Healthcare Partners V, L.P. (" DWHP"), announced today that it is extending the expiration time of its previously announced cash tender offer (the "Tender Offer") in the Offer to Purchase datedDecember 21, 2020 ("Offer to Purchase") for all of the ...

2021-01-22 12:34 9907

Senhwa Announces the First Patient Enrolled in an Investigator Initiated Trial Of Silmitasertib as a Treatment for Patients with Severe COVID-19

TAIPEI and SAN DIEGO, Jan. 21, 2021 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company focused on next generation DNA Damage Response (DDR) therapeutics for the treatment of cancer, today announced that the first patient has enrolled into an investi...

2021-01-22 12:00 2207

Sasakawa Leprosy (Hansen's Disease) Initiative Generates Awareness in Buildup to World Leprosy Day 2021

TOKYO, Jan. 21, 2021 /PRNewswire/ -- With the approach of World Leprosy Day on January 31, 2021, Sasakawa Leprosy (Hansen's Disease) Initiative has created a number of opportunities to amplify the voices of persons affected by leprosy and highlight the issues they face.

2021-01-21 22:00 2010

China Jo-Jo Drugstores Hosts the First Suppliers Conference in China

HANGZHOU, China, Jan. 21, 2021 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD) ("Jo-Jo Drugstores" or the "Company"), a leading online and offline retailer, wholesale distributor of pharmaceutical and other healthcare products and healthcare provider in China, today announced that the...

2021-01-21 21:30 7266
1 ... 246247248249250